financetom
Business
financetom
/
Business
/
Kellanova posts upbeat Q1 results as demand held steady
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kellanova posts upbeat Q1 results as demand held steady
May 2, 2024 6:49 AM

(Reuters) - Pop-Tarts maker Kellanova ( K ) beat Wall Street estimates for first-quarter sales and profit on Thursday, boosted by higher prices and firm demand for its breakfast cereals and ready-to-eat snacks.

The Rice Krispies maker's shares were up nearly 2% in premarket trading.

Kellanova ( K ), which rebranded itself late last year, is known for its diverse portfolio of brands like Grahams Crackers, Nutri-Grain breakfast bars and frozen food like Morningstar Farms.

The company, like other major brands in the packaged food industry, has ramped up prices, banking on the popularity of its premium products among consumers, particularly in North America.

Despite price increases and sticky inflation, consumers remain loyal to their favorite snack brands, shunning cheaper alternatives.

Kellanova ( K ), also home to internationally recognized cereal brands such as Frosties and Special K, said its prices rose by 8.5% in the quarter, while organic sales volumes fell 3.1%.

The strong results echo sentiments from packaged food peer Conagra Brands ( CAG ) that posted upbeat quarterly results last month, helped by a rebound in demand for its pantry staples and frozen foods.

Kellanova's ( K ) snacking business, formerly known as Kellogg, reported net sales of $3.20 billion in the three months ended March 30, above analysts' expectations of $3.16 billion, according to LSEG data.

Higher prices also helped drive its adjusted gross margin to 35.7% from 31.0% a year earlier.

The company, which spun-off its North American cereal business into WK Kellogg last year, posted an adjusted profit of $1.01 per share for the quarter, surpassing expectations of 85 cents per share.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ally Financial's Q2 Adjusted Earnings, Net Revenue Increase
Ally Financial's Q2 Adjusted Earnings, Net Revenue Increase
Jul 18, 2025
07:42 AM EDT, 07/18/2025 (MT Newswires) -- Ally Financial ( ALLY ) reported Q2 adjusted earnings Friday of $0.99 per diluted share, up from $0.73 a year earlier. Analysts polled by FactSet expected $0.81. Net revenue for the quarter ended June 30 was $2.08 billion, compared with $2.02 billion a year earlier. Analysts polled by FactSet expected $2.04 billion. Ally...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Top Premarket Gainers
Top Premarket Gainers
Jul 18, 2025
07:42 AM EDT, 07/18/2025 (MT Newswires) -- Blaize ( BZAI ) stock was up 99% pre-bell Friday after the company said late Thursday it won a contract with a minimum value of $120 million for its hybrid artificial intelligence platform for deployment in Asia. K-Tech Solutions ( KMRK ) shares were 33% higher following a 10% drop in the previous...
Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia
Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia
Jul 18, 2025
July 18 (Reuters) - Bristol Myers Squibb ( BMY ) said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia due to a rare bone marrow cancer. The study did not achieve statistically significant results in helping patients become free from red blood cell transfusions...
Copyright 2023-2026 - www.financetom.com All Rights Reserved